PURPOSE: We determined whether the association between breast density and breast cancer risk and cancer severity differs according to menopausal status and postmenopausal hormone therapy (HT) use. METHODS: We collected data on 587,369 women who underwent 1,349,027 screening mammography examinations; 14,090 women were diagnosed with breast cancer. We calculated 5-year breast cancer risk from a survival model for subgroups of women classified by their Breast Imaging Reporting and Data System (BIRADS) breast density, age, menopausal status, and current HT use, assuming a body mass index of 25 kg/m(2). Odds of advanced (ie, IIb, III, IV) versus early (ie, I, IIa) stage invasive cancer was calculated according to BIRADS density. RESULTS: Breast cancer risk was low among women with low density (BIRADS-1): women age 55 to 59 years, 5-year risk was 0.8% (95% CI, 0.6 to 0.9%) for non-HT users and 0.9% (95% CI, 0.7% to 1.1%) for estrogen and estrogen plus progestin users. Breast cancer risk was high among women with very high density (BIRADS-4), particularly estrogen plus progestin users: women age 55 to 59 years, 5-year risk was 2.4% (95% CI, 2.0% to 2.8%) for non-HT users, 3.0% (95% CI, 2.6% to 3.5%) for estrogen users, and 4.2% (95% CI, 3.7% to 4.6%) for estrogen plus progestin users. Advanced-stage breast cancer risk was increased 1.7-fold for postmenopausal HT users who had very high density (BIRADS-4) compared to those with average density (BIRADS-2). CONCLUSION: Postmenopausal women with high breast density are at increased risk of breast cancer and should be aware of the added risk of taking HT, especially estrogen plus progestin.
PURPOSE: We determined whether the association between breast density and breast cancer risk and cancer severity differs according to menopausal status and postmenopausal hormone therapy (HT) use. METHODS: We collected data on 587,369 women who underwent 1,349,027 screening mammography examinations; 14,090 women were diagnosed with breast cancer. We calculated 5-year breast cancer risk from a survival model for subgroups of women classified by their Breast Imaging Reporting and Data System (BIRADS) breast density, age, menopausal status, and current HT use, assuming a body mass index of 25 kg/m(2). Odds of advanced (ie, IIb, III, IV) versus early (ie, I, IIa) stage invasive cancer was calculated according to BIRADS density. RESULTS:Breast cancer risk was low among women with low density (BIRADS-1): women age 55 to 59 years, 5-year risk was 0.8% (95% CI, 0.6 to 0.9%) for non-HT users and 0.9% (95% CI, 0.7% to 1.1%) for estrogen and estrogen plus progestin users. Breast cancer risk was high among women with very high density (BIRADS-4), particularly estrogen plus progestin users: women age 55 to 59 years, 5-year risk was 2.4% (95% CI, 2.0% to 2.8%) for non-HT users, 3.0% (95% CI, 2.6% to 3.5%) for estrogen users, and 4.2% (95% CI, 3.7% to 4.6%) for estrogen plus progestin users. Advanced-stage breast cancer risk was increased 1.7-fold for postmenopausal HT users who had very high density (BIRADS-4) compared to those with average density (BIRADS-2). CONCLUSION: Postmenopausal women with high breast density are at increased risk of breast cancer and should be aware of the added risk of taking HT, especially estrogen plus progestin.
Authors: Virginia L Ernster; Rachel Ballard-Barbash; William E Barlow; Yingye Zheng; Donald L Weaver; Gary Cutter; Bonnie C Yankaskas; Robert Rosenberg; Patricia A Carney; Karla Kerlikowske; Stephen H Taplin; Nicole Urban; Berta M Geller Journal: J Natl Cancer Inst Date: 2002-10-16 Impact factor: 13.506
Authors: Celine M Vachon; Thomas A Sellers; Robert A Vierkant; Fang-Fang Wu; Kathleen R Brandt Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-11 Impact factor: 4.254
Authors: Norman F Boyd; Gillian S Dite; Jennifer Stone; Anoma Gunasekara; Dallas R English; Margaret R E McCredie; Graham G Giles; David Tritchler; Anna Chiarelli; Martin J Yaffe; John L Hopper Journal: N Engl J Med Date: 2002-09-19 Impact factor: 91.245
Authors: Anne McTiernan; Rowan T Chlebowski; Christopher Martin; Jennifer David Peck; Aaron Aragaki; Etta D Pisano; C Y Wang; Karen C Johnson; Joann E Manson; Robert B Wallace; Mara Z Vitolins; Gerardo Heiss Journal: J Clin Oncol Date: 2009-11-09 Impact factor: 44.544
Authors: Rowan T Chlebowski; Susan L Hendrix; Robert D Langer; Marcia L Stefanick; Margery Gass; Dorothy Lane; Rebecca J Rodabough; Mary Ann Gilligan; Michele G Cyr; Cynthia A Thomson; Janardan Khandekar; Helen Petrovitch; Anne McTiernan Journal: JAMA Date: 2003-06-25 Impact factor: 56.272
Authors: Karla Kerlikowske; Diana L Miglioretti; Rachel Ballard-Barbash; Donald L Weaver; Diana S M Buist; William E Barlow; Gary Cutter; Berta M Geller; Bonnie Yankaskas; Stephen H Taplin; Patricia A Carney Journal: J Clin Oncol Date: 2003-12-01 Impact factor: 44.544
Authors: Rosa Anna DeFilippis; Hang Chang; Nancy Dumont; Joseph T Rabban; Yunn-Yi Chen; Gerald V Fontenay; Hal K Berman; Mona L Gauthier; Jianxin Zhao; Donglei Hu; James J Marx; Judy A Tjoe; Elad Ziv; Maria Febbraio; Karla Kerlikowske; Bahram Parvin; Thea D Tlsty Journal: Cancer Discov Date: 2012-07-09 Impact factor: 39.397
Authors: Solveig Hofvind; Per Skaane; Joann G Elmore; Sofie Sebuødegård; Solveig Roth Hoff; Christoph I Lee Journal: Radiology Date: 2014-04-01 Impact factor: 11.105
Authors: Touseef A Qureshi; Harini Veeraraghavan; Janice S Sung; Jennifer B Kaplan; Jessica Flynn; Emily S Tonorezos; Suzanne L Wolden; Elizabeth A Morris; Kevin C Oeffinger; Malcolm C Pike; Chaya S Moskowitz Journal: J Med Syst Date: 2019-06-22 Impact factor: 4.460
Authors: Deborah J Rhodes; Carmen Radecki Breitkopf; Jeanette Y Ziegenfuss; Sarah M Jenkins; Celine M Vachon Journal: J Clin Oncol Date: 2015-03-02 Impact factor: 44.544
Authors: Hongjie Chen; Lusine Yaghjyan; Christopher Li; Ulrike Peters; Bernard Rosner; Sara Lindström; Rulla M Tamimi Journal: Am J Epidemiol Date: 2021-01-04 Impact factor: 4.897